Pulmonary Fibrosis: Menstrual-Blood MSC Therapy

This briefing explains what the technology is meant to do, who might be discussed for it, and what it does not replace. It is not medical advice and does not promise tumor shrinkage, functional recovery, or a cure. Eligibility, the receiving hospital, and the bill must be confirmed in writing by that hospital. Do not stop standard treatment unless the specialist agrees.

A healthy lung is elastic. Pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), replaces interstitium with scar. People become short of breath on effort and cough dryly; imaging can show honeycombing. Pirfenidone and nintedanib slow some progression. They do not turn established scar back into normal lung. Transplant is limited by donors and surgical risk.

What the briefing says the cells do

Menstrual-blood mesenchymal stromal cells (MenSCs) are isolated and expanded from menstrual blood of a healthy donor of reproductive age. The briefing stresses that collection does not require bone marrow, that allogeneic use is low in immunogenicity, that the patient’s own cells are not required, and that embryos are not involved. The stated actions are anti-inflammatory effects, less fibroblast activation and collagen, and support for injured alveolar epithelium — not “becoming a new lung.” The named site is Shulan (Boao) Hospital in Boao Lecheng. Whether it is offered, and to whom, must be confirmed in writing by that hospital.

1. Pulmonology confirms the fibrosis type, lung function, oxygen need, and high-resolution CT;
2. Antifibrotic drugs, oxygen, and rehabilitation continue; cell therapy is only an exploratory add-on in the source;
3. Active severe infection, uncontrolled cancer, and inability to tolerate infusion are exclusions;
4. Allogeneic MenSCs are given by vein or by the route in the protocol; the hospital sets the dose;
5. Lung function, imaging, exacerbations, and infusion reactions are followed.